Figure 4.
Qualitative (a) and quantitative (b) Western blot of NIX, BNIP3 and Drp1 in C, S, CCI+ HBO, and CCI group. Weakest blot was present in the C and S group and blots became gradually stronger after CCI and especially CCI+HBO therapy (n = 9 rats per group for three repeats, *presented compared with S group, # presented compared with CCI group, P < 0.05).Qualitative (c) and quantitative (d) Western blot of NIX, BNIP3 and Drp1 represented the corresponding groups after AMPK inhibitor CC administration. The blots of BNIP3 presented in the CCI and CCI+HBO group became similar with C and S group (n = 9 rats per group for three repeats, P > 0.05). While the blots of NIX and Drp1 are stronger in CCI and CCI+HBO group than the C and S groups (n = 9 rats per group for three repeats, *presented compared with S group, P < 0.05). There is no significant difference between CCI and CCI+HBO group (n = 9 rats per group for three repeats, P > 0.05). Qualitative (e) and quantitative (f) Western blot of NIX, BNIP3, and Drp1 represented the corresponding groups after CaMMKβ inhibitor STO609 administration. The blots presented in the CCI and CCI+HBO group became similar with C and S group (n = 9 rats per group for three repeats, P > 0.05). CCI: chronic constriction injury; HBO: hyperbaric oxygenation.